Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Forde

Showing results (21-30 of 307) with videos related to

Pageof 31
Sort By:
The Journal of Investigative Dermatology|September 25, 2025
Triggers, Drivers, and Lids: Uncovering the Mechanistic Differentiators between IL-4- and IL-13-Targeted mAbsKarina M Forde, Alan D Irvine
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The International Journal of Targeted Therapies in Cancer|June 25, 2013
Abiraterone for the Treatment of Advanced Prostate CancerPatrick M Forde, Emmanuel S Antonarakis
Nature Reviews. Clinical Oncology|October 19, 2019
Immunotherapy trials in mesothelioma - promising results, but don't stop hereAnna K Nowak, Patrick M Forde
Therapeutic Advances in Medical Oncology|August 27, 2025
The role of immunotherapy in resectable non-small-cell lung cancerConor D Moloney, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Managing acquired resistance in EGFR-mutated non-small cell lung cancerPatrick M Forde, David S Ettinger
Translational Lung Cancer Research|January 23, 2016
Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet needKristen A Marrone, Patrick M Forde
Biotechnology and Applied Biochemistry|September 18, 2007
Enhancing methacrylate-monolith-based downstream processes to champion plasmid DNA productionMichael K Danquah, Gareth M Forde
Briefings in Functional Genomics|January 15, 2013
Next-generation sequencing technologies and their impact on microbial genomicsBrian M Forde, Paul W O'Toole
Expert Opinion on Pharmacotherapy|May 19, 2012
Crizotinib in the treatment of non-small-cell lung cancerPatrick M Forde, Charles M Rudin
Pageof 31

Showing results (21-30 of 307) with videos related to

Sort By:
Pageof 31
The Journal of Investigative Dermatology|September 25, 2025
Triggers, Drivers, and Lids: Uncovering the Mechanistic Differentiators between IL-4- and IL-13-Targeted mAbsKarina M Forde, Alan D Irvine
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The International Journal of Targeted Therapies in Cancer|June 25, 2013
Abiraterone for the Treatment of Advanced Prostate CancerPatrick M Forde, Emmanuel S Antonarakis
Nature Reviews. Clinical Oncology|October 19, 2019
Immunotherapy trials in mesothelioma - promising results, but don't stop hereAnna K Nowak, Patrick M Forde
Therapeutic Advances in Medical Oncology|August 27, 2025
The role of immunotherapy in resectable non-small-cell lung cancerConor D Moloney, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Managing acquired resistance in EGFR-mutated non-small cell lung cancerPatrick M Forde, David S Ettinger
Translational Lung Cancer Research|January 23, 2016
Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet needKristen A Marrone, Patrick M Forde
Biotechnology and Applied Biochemistry|September 18, 2007
Enhancing methacrylate-monolith-based downstream processes to champion plasmid DNA productionMichael K Danquah, Gareth M Forde
Briefings in Functional Genomics|January 15, 2013
Next-generation sequencing technologies and their impact on microbial genomicsBrian M Forde, Paul W O'Toole
Expert Opinion on Pharmacotherapy|May 19, 2012
Crizotinib in the treatment of non-small-cell lung cancerPatrick M Forde, Charles M Rudin
Pageof 31